Numerous clinical trials evaluate minoxidil from Early Phase 1 through Phase 4, focusing primarily on androgenetic alopecia and female pattern hair loss, alongside secondary indications such as acne vulgaris and grey hair repigmentation. Sponsored by diverse commercial and academic institutions, including Applied Biology Inc. and Siriraj Hospital, these studies investigate therapeutic responses and novel delivery formulations. The collective body of research encompasses completed, active, recruiting, withdrawn, and unknown trial statuses.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07758400 | NOT_YET_RECRUITING | Androgenetic Alopecia |
Cheng Zhou |
2027-01-01 | |
| NCT07529977 | NOT_YET_RECRUITING | Androgenetic Alopecia; Androgenetic Alopecia (AGA) |
Eurofarma Laboratorios S.A. |
2027-01-31 | PHASE3 |
| NCT07518342 | NOT_YET_RECRUITING | Androgenetic Alopecia; Androgenetic Alopecia (AGA) |
Assiut University |
2026-04 | PHASE4 |
| NCT07594678 | NOT_YET_RECRUITING | Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Chemotherapy-Induced Alopecia |
Ohio State University Comprehensive Cancer Center |
2026-11-15 | PHASE2 |
| NCT05417308 | RECRUITING | Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Endocrine Therapy-Induced Alopecia; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8 |
Ohio State University Comprehensive Cancer Center |
2023-03-01 | EARLY_PHASE1 |
| NCT07435012 | RECRUITING | Androgenic Alopecia |
Triple Hair Inc |
2026-04 | PHASE3 |
| NCT07080931 | RECRUITING | Androgenetic Alopecia |
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. |
2025-02-24 | PHASE3 |
| NCT07264790 | RECRUITING | Breast Reconstruction; Perfusion; Complications; High Risk for Breast Cancer; Genetic Predisposition |
Duke University |
2026-03-16 | PHASE1 |
| NCT05778825 | ACTIVE_NOT_RECRUITING | Survivors of Childhood Cancer; Alopecia |
Memorial Sloan Kettering Cancer Center |
2023-03-10 | PHASE2 |
| NCT07548918 | NOT_YET_RECRUITING | Vitiligo - Macular Depigmentation |
Sohag University |
2026-05-20 | PHASE2 |
| NCT07370519 | RECRUITING | Androgenetic Alopecia (AGA) |
Shenzhen People's Hospital |
2026-01-25 | PHASE2 |
| NCT07536100 | RECRUITING | Androgenetic Alopecia (AGA) |
Institute of Dermatology, Thailand |
2026-05-05 | |
| NCT04207931 | RECRUITING | Central Centrifugal Cicatricial Alopecia (CCCA) |
Wake Forest University Health Sciences |
2018-04-30 | PHASE4 |
| NCT07563036 | RECRUITING | Androgenetic Alopecia; Androgenic Alopecia |
Kasr El Aini Hospital |
2026-02-01 | |
| NCT07203599 | RECRUITING | Androgenic Alopecia |
Shenzhen People's Hospital |
2025-09-20 | PHASE1; PHASE2 |
| NCT07502976 | RECRUITING | Androgenic Alopecia |
Kasr El Aini Hospital |
2026-01-01 | |
| NCT05888922 | RECRUITING | Androgenetic Alopecia; Female Pattern Baldness |
Industrial Farmacéutica Cantabria, S.A. |
2024-10-17 | PHASE3 |
| NCT07785869 | ACTIVE_NOT_RECRUITING | Hair Characteristics |
Pacagen, Inc. |
2026-01-26 | |
| NCT07459933 | NOT_YET_RECRUITING | Alopecia Areata |
Jinnah Postgraduate Medical Centre |
2026-03-15 | PHASE4 |
| NCT07373054 | COMPLETED | Androgenic Alopecia |
Fujian Medical University Union Hospital |
2025-11-06 | |
| NCT06924632 | COMPLETED | Androgenetic Alopecia; Male Pattern Baldness |
Samson Clinical Operations Pty Ltd |
2025-07-14 | PHASE3 |
| NCT07273799 | NOT_YET_RECRUITING | Androgenic Alopecia |
Sheikh Zayed Federal Postgraduate Medical Institute |
2025-12-20 | PHASE3 |
| NCT04594018 | RECRUITING | Androgenetic Alopecia |
EMS |
2023-02-02 | PHASE3 |
| NCT07012486 | RECRUITING | Androgenetic Alopecia (AGA) |
Shanghai Zhongshan Hospital |
2025-06 | EARLY_PHASE1 |
| NCT06813963 | COMPLETED | Grey Hair |
Southern Medical University, China |
2025-02-15 | PHASE4 |
| NCT07056933 | NOT_YET_RECRUITING | Alopecia |
Cairo University |
2025-07-08 | |
| NCT06501924 | NOT_YET_RECRUITING | Androgenetic Alopecia; Female Pattern Baldness; Male Pattern Baldness |
Applied Biology, Inc. |
2025-01-15 | PHASE3 |
| NCT07018349 | NOT_YET_RECRUITING | Androgenetic Alopecia (AGA) |
Jinnah Postgraduate Medical Centre |
2025-06-15 | |
| NCT07076706 | COMPLETED | Male Pattern of Hair Loss, Androgenic Alopecia; Androgenetic Alopecia (AGA) |
Beijing Dayspring Pharmaceutical Technology Co., Ltd |
2024-12-05 | PHASE2 |
| NCT07011485 | ACTIVE_NOT_RECRUITING | Alopecia, Androgenetic; Baldness; Androgenetic Alopecia (AGA) |
PDFE Pharma Innovations FZCO |
2025-05-14 | PHASE2 |
| NCT06826001 | NOT_YET_RECRUITING | Androgenetic Alopecia |
Sheikh Zayed Medical College |
2025-02 | PHASE2 |
| NCT06556056 | COMPLETED | Androgenic Alopecia |
NovoBliss Research Pvt Ltd |
2024-06-30 | |
| NCT06552039 | COMPLETED | Hair Fall and Pre-mature Graying |
NovoBliss Research Pvt Ltd |
2024-12-26 | |
| NCT05272462 | UNKNOWN | Ovarian Cancer |
Loyola University |
2021-12-13 | PHASE2 |
| NCT06679556 | COMPLETED | Pharmacokinetic |
Samson Clinical Operations Pty Ltd |
2024-11-06 | PHASE1 |
| NCT06484881 | WITHDRAWN | Androgenetic Alopecia; Female Pattern Baldness |
Applied Biology, Inc. |
2024-09-15 | PHASE3 |
| NCT06218394 | UNKNOWN | Androgenetic Alopecia |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2023-12-14 | |
| NCT06218498 | UNKNOWN | Androgenetic Alopecia |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2023-11-24 | |
| NCT07776015 | COMPLETED | Androgenetic Alopecia; Exosomes |
Tanta University |
2023-04-20 | |
| NCT06333600 | UNKNOWN | Dermatology; Female Pattern Baldness |
Sohag University |
2023-05-20 | PHASE1; PHASE2 |
| NCT05636904 | COMPLETED | Androgenetic Alopecia |
Dermaliq Therapeutics, Inc. |
2022-12-05 | PHASE1; PHASE2 |
| NCT06015516 | COMPLETED | Healthy |
Industrial Farmacéutica Cantabria, S.A. |
2024-02-09 | PHASE1 |
| NCT04721548 | COMPLETED | Alopecia |
Eurofarma Laboratorios S.A. |
2023-03-02 | PHASE3 |
| NCT03831334 | ACTIVE_NOT_RECRUITING | Permanent Chemotherapy-induced Alopecia |
Northwestern University |
2019-04-09 | EARLY_PHASE1 |
| NCT05587257 | UNKNOWN | Alopecia Areata |
Assiut University |
2023-01-01 | |
| NCT05827991 | UNKNOWN | Androgenic Alopecia |
Xijing Hospital |
2022-03-01 | |
| NCT06108193 | UNKNOWN | Acne Vulgaris |
Chang Gung Memorial Hospital |
2023-07-11 | PHASE1; PHASE2 |
| NCT06066827 | UNKNOWN | Androgenetic Alopecia |
Dr. dr. Lili Legiawati, SpKK(K) |
2023-08-14 | |
| NCT05990400 | UNKNOWN | Androgenetic Alopecia |
Indonesia University |
2023-05-01 | PHASE2; PHASE3 |
| NCT06043349 | UNKNOWN | Androgenetic Alopecia |
Indonesia University |
2023-06-01 | PHASE4 |
| NCT05989165 | COMPLETED | Androgenetic Alopecia |
Indonesia University |
2023-06-01 | PHASE3 |
| NCT05864885 | UNKNOWN | Androgenetic Alopecia |
Aneira Pharma, Inc. |
2023-06-09 | PHASE1 |
| NCT03852992 | WITHDRAWN | Male Pattern Hair Loss; Androgenetic Alopecia; Male Pattern Baldness |
University of Minnesota |
2022-09-30 | PHASE2 |
| NCT05790941 | UNKNOWN | Hypotrichosis |
Aneira Pharma, Inc. |
2023-03-11 | EARLY_PHASE1 |
| NCT05435625 | UNKNOWN | Androgenic Alopecia |
Kasr El Aini Hospital |
2022-01-01 | |
| NCT05369481 | UNKNOWN | Androgenic Alopecia |
Mohammed Abd El Mawgoud Amer |
2022-03-01 | |
| NCT06527729 | COMPLETED | Alopecia Areata |
Assiut University |
2021-07-01 | EARLY_PHASE1 |
| NCT05296863 | COMPLETED | Alopecia, Androgenetic; Hair Loss/Baldness |
Dr. dr. Lili Legiawati, SpKK(K) |
2021-10-11 | PHASE3 |
| NCT04481412 | COMPLETED | Androgenetic Alopecia |
Cairo University |
2020-07-25 | PHASE2; PHASE3 |
| NCT04293822 | UNKNOWN | Androgenetic Alopecia |
Assiut University |
2020-06 | PHASE4 |
| NCT04209803 | COMPLETED | Androgenetic Alopecia |
Kafrelsheikh University |
2018-12-01 | PHASE4 |
| NCT03753113 | COMPLETED | Androgenetic Alopecia |
Farid Masoud |
2018-11-28 | PHASE3 |
| NCT03528772 | COMPLETED | Anal Fissure |
Mansoura University |
2018-05-10 | |
| NCT02483195 | WITHDRAWN | Female Androgenetic Alopecia |
University of Florida |
2016-08 | PHASE4 |
| NCT03488108 | COMPLETED | Alopecia |
Mayo Clinic |
2017-01-23 | PHASE1; PHASE2 |
| NCT03535233 | COMPLETED | Alopecia Areata |
Cairo University |
2016-03 | PHASE4 |
| NCT02154503 | UNKNOWN | Androgenetic Alopecia |
Vancouver General Hospital |
2014-04 | PHASE1 |
| NCT02486848 | WITHDRAWN | Female Pattern Hair Loss; Androgenetic Alopecia |
Maja Kovacevic, MD |
2016-06 | |
| NCT04090801 | COMPLETED | Female Pattern Hair Loss |
Sohag University |
2015-05-30 | PHASE4 |
| NCT02279823 | COMPLETED | Androgenetic Alopecia |
Intrepid Therapeutics, Inc. |
2014-10 | PHASE2 |
| NCT02460289 | COMPLETED | Male Pattern of Hair Loss, Androgenic Alopecia |
Galderma R&D |
2015-05-19 | |
| NCT02460497 | COMPLETED | Female Pattern Hair Loss, Androgenic Alopecia |
Galderma R&D |
2015-05-27 | |
| NCT02283645 | UNKNOWN | Chest Hair Enhancement |
Mae Fah Luang University Hospital |
2015-01 | PHASE4 |
| NCT02275832 | COMPLETED | Beard Enhancement |
Mae Fah Luang University Hospital |
2014-11 | PHASE4 |
| NCT00876200 | COMPLETED | Williams Beuren Syndrome |
Hospices Civils de Lyon |
2009-03 | PHASE2 |
| NCT02280603 | COMPLETED | Androgenetic Alopecia |
Dong-A ST Co., Ltd. |
2014-01 | PHASE1; PHASE2 |
| NCT02198261 | Completed | Androgenetic Alopecia |
Applied Biology Inc. |
2014-07 | -- |
| NCT02206802 | Completed | Alopecia|Female Pattern Hair Loss |
Applied Biology Inc. |
2014-07 | -- |
| NCT01924000 | COMPLETED | Eyebrow Hypotrichosis; Thin Eyebrow |
Mae Fah Luang University Hospital |
2013-12 | PHASE4 |
| NCT01655108 | UNKNOWN | Female Pattern Alopecia |
Brasilia University Hospital |
2012-03 | PHASE3 |
| NCT01900041 | COMPLETED | Female Pattern Hair Loss; Androgenetic Alopecia (AGA); Ludwig Type 1; Ludwig Type 2 |
Merz Pharmaceuticals GmbH |
2012-04 | PHASE2 |
| NCT01319370 | COMPLETED | Androgenetic Alopecia |
Natalie GARCIA BARTELS |
2010-11 | PHASE2 |
| NCT01650272 | UNKNOWN | Objective (Goal); Self-Assessment; Adverse Effects |
Siriraj Hospital |
2012-06 | PHASE1; PHASE2 |
| NCT01672307 | COMPLETED | Hypotrichosis of Eyebrows; Thinning Eyebrows |
Mae Fah Luang University Hospital |
2012-09 | PHASE4 |
| NCT01643629 | UNKNOWN | Androgenetic Alopecia |
Kasiak Research Pvt. Ltd. |
2012-01 | PHASE1; PHASE2 |
| NCT01662089 | UNKNOWN | Female Pattern Alopecia |
Siriraj Hospital |
2012-01 | PHASE1; PHASE2 |
| NCT01325337 | COMPLETED | Alopecia; Alopecia, Androgenetic; Baldness |
Allergan |
2011-06 | PHASE2 |
| NCT01325350 | COMPLETED | Alopecia; Baldness |
Allergan |
2011-06 | PHASE2 |
| NCT01650272 | Unknown status | Objective (Goal)|Self-Assessment|Adverse Effects |
Siriraj Hospital |
2012-06 | Phase 1|Phase 2 |
| NCT01309191 | COMPLETED | Androgenetic Alopecia |
University Hospitals Cleveland Medical Center |
2011-04 | |
| NCT01391156 | COMPLETED | Androgenetic Alopecia |
Mae Fah Luang University Hospital |
2011-03 | PHASE3 |
| NCT01451125 | COMPLETED | Androgenetic Alopecia; Male Pattern Baldness; Female Pattern Baldness |
Aderans Research Institute |
2010-05 | PHASE2 |
| NCT01145625 | COMPLETED | Alopecia |
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. |
2010-06 | PHASE3 |
| NCT01226459 | COMPLETED | Androgenetic Alopecia |
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. |
2010-09 | PHASE3 |
| NCT01309191 | Completed | Androgenetic Alopecia |
University Hospitals Cleveland Medical Center|University of California San Francisco|Kaiser Permanente |
2011-04 | Not Applicable |
| NCT00175617 | COMPLETED | Female Pattern Hair Loss |
University of British Columbia |
2005-09 | PHASE2 |
| NCT00958750 | COMPLETED | Androgenetic Alopecia; Female Pattern Hair Loss |
Charite University, Berlin, Germany |
2008-06 | PHASE3 |
| NCT00607477 | TERMINATED | Treatment Induced Hypertension |
University of Chicago |
2008-01 | |
| NCT00151515 | COMPLETED | Androgenetic Alopecia |
Johnson & Johnson Consumer and Personal Products Worldwide |
2003-10 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2026-08-11)
Check the
Minoxidil
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.